{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:36:47Z","timestamp":1792784207635,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Biostatistics and Bioinformatics Shared Resource of the University of Kentucky Markey Cancer Center","award":["P30CA177558"],"award-info":[{"award-number":["P30CA177558"]}],"id":[{"id":"https:\/\/ror.org\/02k3smh20","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12094-019-02060-8","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T06:28:42Z","timestamp":1550644122000},"page":"1336-1342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Multiple sclerosis outcomes after cancer immunotherapy"],"prefix":"10.1007","volume":"21","author":[{"given":"Catherine R.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Jayswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell B.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-0093","authenticated-orcid":false,"given":"John L.","family":"Villano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"2060_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med"},{"key":"2060_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"2060_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med"},{"key":"2060_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"2060_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350.","journal-title":"Lancet"},{"key":"2060_CR6","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270\u20131.","journal-title":"N Engl J Med"},{"key":"2060_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, Mcdermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"2060_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"2060_CR9","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"2060_CR10","doi-asserted-by":"crossref","unstructured":"Gulley JL, Madan RA, Pachynski R et al. (2017) Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J Natl Cancer Institute 109","DOI":"10.1093\/jnci\/djw261"},{"key":"2060_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1074-7613(04)00116-5","volume":"20","author":"SJ Khoury","year":"2004","unstructured":"Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 2004;20:529\u201338.","journal-title":"Immunity"},{"key":"2060_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","volume":"86","author":"Y Cao","year":"2016","unstructured":"Cao Y, Nylander A, Ramanan S, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology. 2016;86:1553\u20136.","journal-title":"Neurology"},{"key":"2060_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.24715","volume":"80","author":"LA Gerdes","year":"2016","unstructured":"Gerdes LA, Held K, Beltran E, et al. CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis. Ann Neurol. 2016;80:294\u2013300.","journal-title":"Ann Neurol"},{"key":"2060_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"Anonymous","year":"2017","unstructured":"Anonymous. Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Neurology. 2017;16:877\u201397.","journal-title":"The Lancet. Neurology"},{"key":"2060_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/ana.24163","volume":"75","author":"I Metz","year":"2014","unstructured":"Metz I, Weigand SD, Popescu BF, et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol. 2014;75:728\u201338.","journal-title":"Ann Neurol"},{"key":"2060_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1001\/archneur.61.10.1613","volume":"61","author":"HL Weiner","year":"2004","unstructured":"Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 2004;61:1613\u20135.","journal-title":"Arch Neurol"},{"key":"2060_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1055\/s-0036-1579693","volume":"36","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Munger KL. Epidemiology of multiple sclerosis: from risk factors to prevention\u2014an update. Semin Neurol. 2016;36:103\u201314.","journal-title":"Semin Neurol"},{"key":"2060_CR18","doi-asserted-by":"crossref","unstructured":"Kwek SS, Dao V, Roy R et al. (2012) Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol 189:3759\u20133766","DOI":"10.4049\/jimmunol.1201529"},{"key":"2060_CR19","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189\u201399.","journal-title":"N Engl J Med"},{"key":"2060_CR20","doi-asserted-by":"publisher","first-page":"e0120827","DOI":"10.1371\/journal.pone.0120827","volume":"10","author":"G Numico","year":"2015","unstructured":"Numico G, Cristofano A, Mozzicafreddo A, et al. Hospital admission of cancer patients: avoidable practice or necessary care? PLoS ONE. 2015;10:e0120827.","journal-title":"PLoS ONE"},{"key":"2060_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22:709\u201318.","journal-title":"Oncologist"},{"key":"2060_CR22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017;28:377\u201385.","journal-title":"Ann Oncol"},{"key":"2060_CR23","doi-asserted-by":"publisher","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE. 2013;8:e53745.","journal-title":"PLoS ONE"},{"key":"2060_CR24","doi-asserted-by":"crossref","unstructured":"Zimmer L, Goldinger SM, Hofmann L et al. (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer (Oxford, England 1990) 60:210\u2013225","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"2060_CR25","doi-asserted-by":"crossref","unstructured":"Fellner A, Makranz C, Lotem M et al. (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol","DOI":"10.1007\/s11060-018-2752-5"},{"key":"2060_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-oncology. 2014;16:589\u201393.","journal-title":"Neuro-oncology"},{"key":"2060_CR27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1056\/NEJM200009283431307","volume":"343","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938\u201352.","journal-title":"N Engl J Med"},{"key":"2060_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ncl.2010.12.010","volume":"29","author":"SV Ramagopalan","year":"2011","unstructured":"Ramagopalan SV, Sadovnick AD. Epidemiology of multiple sclerosis. Neurol Clin. 2011;29:207\u201317.","journal-title":"Neurol Clin"},{"key":"2060_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci"},{"key":"2060_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","volume":"34","author":"M Sarangdhar","year":"2016","unstructured":"Sarangdhar M, Tabar S, Schmidt C, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol. 2016;34:697\u2013700.","journal-title":"Nat Biotechnol"},{"key":"2060_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/apt.14504","volume":"47","author":"L Harinstein","year":"2018","unstructured":"Harinstein L, Wu E, Brinker A. Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder. Aliment Pharmacol Ther. 2018;47:809\u201315.","journal-title":"Aliment Pharmacol Ther"},{"key":"2060_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1352458514549403","volume":"21","author":"EJ Gettings","year":"2015","unstructured":"Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Multiple sclerosis (Houndmills, Basingstoke, England). 2015;21:670.","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"2060_CR33","unstructured":"G\u00f3mez Vicente L, Rubio Viqueira B, Jimenez De Las Pe\u00f1as M et al. (2016) P04.07\u2002Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab. Neuro-oncology 18:iv25\u2013iv25"},{"key":"2060_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"2060_CR35","doi-asserted-by":"crossref","unstructured":"Zehou O, Leibler C, Arnault JP et al. (2018) Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. Am J Transpl","DOI":"10.1111\/ajt.15071"},{"key":"2060_CR36","doi-asserted-by":"crossref","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al. (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer (Oxford, England 1990) 73:1\u20138","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"2060_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/neuonc\/nox115","volume":"20","author":"AM Zukas","year":"2018","unstructured":"Zukas AM, Schiff D. Neurological complications of new chemotherapy agents. Neuro-oncology. 2018;20:24\u201336.","journal-title":"Neuro-oncology"},{"key":"2060_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"2060_CR39","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) Antibodies. JAMA Neurol. 2017;74:1216\u201322.","journal-title":"JAMA Neurol"},{"key":"2060_CR40","doi-asserted-by":"crossref","unstructured":"Haanen J, Carbonnel F, Robert C et al. (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119\u2013iv142","DOI":"10.1093\/annonc\/mdx225"},{"key":"2060_CR41","unstructured":"Tobin WO, Pittock SJ (2017) autoimmune neurology of the central nervous system. Continuum (Minneapolis, Minn.) 23:627\u2013653"},{"key":"2060_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234\u201340.","journal-title":"JAMA Oncol"},{"key":"2060_CR43","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdx377.007","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368\u201376.","journal-title":"Ann Oncol"},{"key":"2060_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/CMR.0000000000000410","volume":"28","author":"JC Kuo","year":"2018","unstructured":"Kuo JC, Lilly LB, Hogg D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. Melanoma Res. 2018;28:61\u20134.","journal-title":"Melanoma Res"},{"key":"2060_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13256-017-1229-z","volume":"11","author":"V Kwatra","year":"2017","unstructured":"Kwatra V, Karanth NV, Priyadarshana K, et al. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. J Med Case Rep. 2017;11:73.","journal-title":"J Med Case Rep"},{"key":"2060_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jaut.2010.07.003","volume":"36","author":"Y Shoenfeld","year":"2011","unstructured":"Shoenfeld Y, Agmon-Levin N. 'ASIA'\u2014autoimmune\/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4\u20138.","journal-title":"J Autoimmun"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02060-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02060-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02060-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T19:12:44Z","timestamp":1582139564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02060-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2060"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02060-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patient consent was not obtained from our institutional case, since the patient passed away many years prior to preparation of this manuscript. Data are de-identified in\n                      \n                      and patient consent is not applicable. Our study does not include any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}